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The mammalian sirtuin family, consist-
ing of NAD+-dependent class III his-
tone/protein deacetylases, has 7 members
(Greiss and Gartner, 2009). The physio-
logical activities and pathological associ-
ations of sirtuins have been subjects of
intense interest, as these are key regulators
of metabolic processes that often impinge
on health, aging and lifespan (Chalkiadaki
and Guarente, 2012; Houtkooper et al.,
2012). Perhaps the least investigated of the
sirtuins is SIRT7. Like its more illustrious
family member SIRT1, SIRT7 is nuclear
localized. More specifically, it is enriched
in the nucleolus (Ford et al., 2006; Barber
et al., 2012; Ryu et al., 2014). Functionally,
SIRT7 was first described by Guarente’s
group to be associated with active ribo-
somal RNA genes (or rDNA), where it
interacts with RNA polymerase I and pos-
itively regulate its transcription activity
(Ford et al., 2006). SIRT7 also interacts
directly with the rDNA transcription fac-
tor upstream binding factor (UBF), and
is responsible for resuming rDNA tran-
scription, suppressed during cell divi-
sion, upon mitotic exit (Grob et al.,
2009). Proteomics analyses indicate that
SIRT7 is also associated with several
nucleolus-localized chromatin remodel-
ing complexes (Tsai et al., 2012) and is
involved in multiple components of path-
ways regulating ribosome biogenesis and
protein translation (Tsai et al., 2014).
Other recent findings have also impli-
cated a role for SIRT7 in regulating aspects
of cell survival in multiple tissue/organ
systems. Like SIRT1, SIRT7 deacetylates
p53, and in this regard appears to
be cardioprotective. Sirt7 knockout mice
were shown to exhibit reduced lifes-
pan with frequent development of heart
hypertrophy and inflammatory cardiomy-
opathy (Vakhrusheva et al., 2008). SIRT7
also deacetylates the acetylated lysine 18 of
histone H3, and together with its associa-
tion with E26 transformed specific (ETS)
domain containing transcription factor
ELK4 and perhaps other tumor suppres-
sor factors, appears to promote a state of
malignancy (Barber et al., 2012).
A particular interesting set of recent
papers (Shin et al., 2013; Ryu et al., 2014;
Yoshizawa et al., 2014) reported find-
ings on the role of SIRT7 in metabolic
regulation, particularly the regulation of
lipid and energy metabolism in the liver.
These papers together clearly suggest a
vital role for SIRT7 in hepatic lipid
metabolism, which is in line with ear-
lier data showing that the liver has the
highest levels of Sirt7 transcripts among
adult mice tissues (Ford et al., 2006).
However, these findings are also intriguing
in the way they contradict each other. One
of these papers reached an almost com-
pletely opposite conclusion on the role of
SIRT7 in hepatic lipid metabolism from
the other two. Even amongst the two
that were in general agreement with each
other, the elucidated mechanisms differ
significantly.
Yoshizawa et al. (2014) studied Sirt7
knockout (KO) mouse generated pre-
viously by Braun’s group (Vakhrusheva
et al., 2008) (deleting exons 4–9), which
is extensively backcrossed to a C57/BL6
background. They observed that these
Sirt7 KO mice were resistant to high fat
diet (HFD)-induced liver steatosis (fatty
liver), obesity and glucose intolerance, and
showed significantly lower hepatic triglyc-
eride (TG) content compared to wild type.
The livers of HFD-fed Sirt7 KO mice
has decreased expression of TG synthe-
sis and lipid storage genes, such as CD36
(which is crucial for fatty acid uptake), as
well as the cell-death-inducing DFFA-like
effector (CIDE) A and C (which func-
tions in lipid storage and lipid droplet
formation). The authors also generated
liver-specific conditional knockout mice
(floxed Sirt7 crossed with albumin pro-
moter driven Cre recombinase, or LCKO
mice), and these likewise exhibited a sim-
ilar phenotype of reduced hepatic TG
and lipid droplets after HFD feeding. The
authors found that SIRT7 positively regu-
lates the orphan nuclear receptor testicular
receptor 4 (TR4), and it activates multi-
ple TR4 target genes to increase fatty acid
uptake and TG biosynthesis and storage.
This is achieved through SIRT7’s inter-
action with an E3 ubiquitin ligase com-
plex (the DDB1-CUL4-associated factor
1 (DCAF1)/damage-specific DNA bind-
ing protein 1 (DDB1)/cullin 4B (CUL4B)
complex) (Lee and Zhou, 2007) which
inhibits TR4 degradation. TR4 levels are
reduced in SIRT7-deficient liver, and
the steatosis-resistant phenotype could be
explained by a decreased expression of
lipid synthesis and storage genes.
Two other studies, however, presented
findings that contradicted the above. Shin
and colleagues generated another Sirt7
knockoutmouse strain (by replacing exons
4–11 with a LacZ gene), but observed
instead that these mice develop liver
steatosis (Shin et al., 2013). Livers of
these Sirt7 knockout mice have elevated
TG levels, increased expression of inflam-
matory markers, and increased expres-
sion of lipogenic genes. These mice also
have, paradoxically, a serum TG level that
is 4-fold lower than wild type, which
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is likely due to reduce secretion of the
TG transporter very low density glycopro-
tein (VLDL). Hepatocyte specific rescue of
the SIRT7 deficiency with targeted adeno-
associated virus 8 (AAV8)-mediated Sirt7
expression was able to reverse the pheno-
type. The authors noted potential binding
sites for X-box binding protein 1 (XBP1),
a key regulator of the unfolded protein
response (UPR) in the Sirt7 promoter,
and found that ER stress upregulates Sirt7
in a XBP1 dependent manner. They fur-
ther found that ER stress underlies the
development of steatosis in their Sirt7
deficient mice, as the Sirt7 deficient liv-
ers have increased ER stress that could
be partially rescued by a small molecule
chaperone, and viral mediated transgenic
expression of Sirt7. Sirt7 over-expression
could also reverse steatosis induced by a
high-fat diet (HFD). The authors provided
evidence for an underlying mechanism
for their observations. They showed that
the protooncogene product c-Myc recruits
SIRT7 at the promoters of ribosomal pro-
teins to mediate chromatin remodeling
and transcriptional repression of these,
which suppresses ER stress.
In another study, Ryu and colleagues
generated a different Sirt7 knockout
mouse (deleting exons 6–9), and like-
wise observed that these suffered from
liver microvesicular steatosis, with ele-
vated plasma TG and free fatty acids (Ryu
et al., 2014). These authors, however,
noted a more general metabolic defect
in their Sirt7 knockout mice that is asso-
ciated with mitochondrial dysfunction,
such as elevated blood lactate levels and
reduced mitochondrial electron transport
chain Complex I, which could be rescued
by viral-mediated transgenic expression
of Sirt7. SIRT7 levels correlated with the
levels of mitochondrial ribosomal pro-
tein genes, and ChIP-seq demonstrates
that SIRT7 is associated with the promot-
ers of 232 genes encoding mitochondrial
proteins. The effects of SIRT7 on mito-
chondrial homeostasis were apparently
due to SIRT7’s deacetylation of GA-
binding protein (GABP) β1, a regulator of
multiple nuclear-encoded mitochondrial
genes. GABPβ1 deacetylation facilitates its
complex formation with the ETS-domain
containing GABPα, and the transcrip-
tional activation of the GABPα/GABPβ
heterotetrameric complex. SIRT7 appears
therefore to be important in metabolic
regulation at a more fundamental level,
namely that of mitochondrial home-
ostasis. Hepatic lipid metabolism defects
could be just one manifestation of SIRT7
deficiency.
The findings described above, while
clearly pointing toward an important role
for SIRT7 in hepatic lipid metabolism, is
perplexing in terms of the contradicting
conclusions. Differences in genetic back-
ground could on occasions contribute to
phenotype differences like such, but in
this case is unlikely to be a key expla-
nation. Several points about the report
of Yoshizawa and colleagues deserved
to be mentioned. Firstly, the seemingly
hepato-protective phenotype of the Sirt7
knockout mice (Yoshizawa et al., 2014)
itself contrasted the cardiopathic and lifes-
pan reduction phenotype observed ear-
lier by the Braun group (Vakhrusheva
et al., 2008). While it is conceivable that
SIRT7’s actions are somewhat different in
these two tissues, one would expect some
degree of similarity in terms of system-
ically chronic inflammation and stress,
which presumably underlie the reduced
lifespan. In view of the generally unfa-
vorable health effect of the Sirt7 knock-
out (Vakhrusheva et al., 2008), analysis
of how SIRT7 deficiency would affect the
liver may be best done with a liver-specific
conditional knockout. The authors have
generated precisely such a liver-specific
knockout line (LCKO) (Yoshizawa et al.,
2014), but the data associated with the
LCKOs were rather limited. It should also
be noted that liver-specific Sirt7 KO mice
generated by Ryu et al. had microvesicular
steatosis just like the global KO mice (Ryu
et al., 2014).
It is conceivable that SIRT7’s activ-
ity may occur in crosstalk or in tan-
dem with other nuclear sirtuins. In this
regard, SIRT1 is of particular interest, as
its activity is known to mobilize stored
lipids and protects against a high fat
diet, albeit acting largely in adipose tis-
sues and muscle (Pfluger et al., 2008).
The results of Yoshizawa and colleagues
would suggest that SIRT1 and SIRT7 have
opposing effects in lipid metabolism, the
former being catabolic while the later
driving synthesis and storage. The Braun
group had earlier presented a conference
poster highlighting findings that SIRT7
may promote adipogenesis by binding to
and inhibiting SIRT1 (Bober et al., 2012).
The full paper has not yet appeared in
print though, and the physical and func-
tional association between these two sirtu-
ins in the liver has remained unclear.
SIRT7 appears to have, overall, a
protective and prosurvival function
(Vakhrusheva et al., 2008; Kiran et al.,
2014). This, together with its high levels of
expression in liver, makes the notion of a
beneficial function of SIRT7 in this organ
somewhat more palatable. In this regard,
SIRT7’s regulation of mitochondrial func-
tion as elucidated by Ryu and colleagues
may be particularly relevant. Again, one
can draw broad similarities here between
SIRT7 and SIRT1. SIRT1 has a role in
mitochondrial biogenesis (Brenmoehl
and Hoeflich, 2013), and its deacetyla-
tion of peroxisome proliferator-activated
receptor-gamma coactivator-1α (PGC-
1α) has been shown to be required for
activation of mitochondrial fatty acid oxi-
dation genes (Gerhart-Hines et al., 2007).
As SIRT1 and SIRT7 activities are both
regulated by the availability of NAD+,
these sirtuins will likely be co-modulated
by cellular energy status and patholog-
ical conditions that affect this status. It
is also likely that Sirt1 and SIRT7 have
an overlapping repertoire of substrates,
with p53 amongst those already known,
and others will likely be revealed soon.
In terms of systemic aging and lifespan,
loss of Sirt7 (Vakhrusheva et al., 2008)
resulted in a short lifespan phenotype
that broadly parallel that of loss of Sirt1
(Cheng et al., 2003) It would be somewhat
incomprehensible if these two sirtuins reg-
ulate metabolic transcriptional profiles
in ways that are diametrically oppo-
site instead of complementary to each
other.
Although puzzling, the discrepancies
between the different findings discussed
above is likely to be resolved soon with
rapid advances in this field. We may soon
see reports of lipid metabolism profiling of
liver specific knockout and overexpression
of Sirt7 in different genetic backgrounds
of metabolic dysfunction, such as the lep-
tin mutant ob/ob. Resolution of these
discrepancies would be important if
SIRT7 is to be exploited as a therapeutic
target in treatment of metabolic
disorders.
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